

## CONTENTS

*Contributors vii*

*Series Foreword ix*

*Preface xi*

*Chapter 1 Basics of Nuclear Medicine Physics and Radiation Safety 1*

*The Atomic Structure 1*

*Radioactive decay 1*

*Isomeric transition 2*

*Positron decay 2*

*Electron capture 2*

*Characteristic X-rays 3*

*Radioactivity 3*

*Universal decay table 3*

*Radioactivity Equilibrium 4*

*Interaction of radiation with matter 4*

*Radiation safety 5*

*Radiation exposure limits 5*

*Release of patients following I-131 therapy 6*

*Radiation Safety Fundamentals 6*

*Radiation monitoring 6*

*Radiation exposure to pregnant personnel 6*

*Area designation and posting 6*

*Controlled area 6*

*Restricted area 6*

*Radiation area 7*

*High radiation area 7*

*Radioactive materials 7*

*Ordering, receipt, and disposal of radioactive materials 7*

*Radiation safety surveys 7*

*Waste disposal 7*

*Spill of radioactive materials 8*

*Minor spills 8*

*Major spills 8*

*Medical events 8*

*Chapter Self-Assessment Questions 9*

*Chapter 2 Basics of Radiochemistry 11*

*Introduction 11*

*Basic Concepts of Radionuclide 11*

*Atomic nucleus 11*

*Forces in the nucleus 12*

*Isotopes and radioactive decay 12xiv Contents*

*Interaction of radiation with matter 12*

*Production of radionuclides 13*

*Basic Concepts of Radiolabeling 13*

*Isotopic labeling 13*

*Nonisotopic labeling 13*

*Specific activity 13*

*Radiochemistry for positron emission tomography tracers 14*

*Radionuclide selection 14*

*Radiochemistry with positron emission tomography radionuclides 14*

*Radiolabeling with F-18 14*

*Nucleophilic reactions 14*

*Electrophilic reactions 16*

*Radiolabeling using prosthetic agents 16*

*Automation radiosynthesis 16*

*Radiolabeling with C-11 17*

*Radiolabeling with other positron emission tomography radionuclides 17*

*Radiopharmaceuticals 18*

*Quality Control of Radiopharmaceuticals 18*

*Chapter Self-Assessment Questions 21*

*Chapter 3 Basics of Instrumentation 22*

*Introduction 22*

*Gas detectors 22*

*Geiger–Muller survey meters 23*

<i>Scintillation detectors</i>	25
<i>Pulse height analyzer</i>	26
<i>Gamma cameras</i>	26
<i>Collimator geometry</i>	27
<i>Scintillation crystal</i>	28
<i>Photomultiplier tubes</i>	28
<i>Energy and position logic computer</i>	28
<i>Single-photon emission computed tomography</i>	28
<i>Single-photon emission computed tomography image quality</i>	28
<i>Positron emission tomography</i>	29
<i>Problems with reconstruction of positron emission tomography images</i>	29
<i>Positron emission tomography/computed tomography instrumentation</i>	30
<i>Time of flight positron emission tomography/computed tomography</i>	31
<i>Chapter Self-Assessment Questions</i>	32
<i>Chapter 4 Thyroid Imaging and Therapy</i>	34
<i>Introduction</i>	34
<i>Hyperthyroidism</i>	34
<i>Background</i>	34
<i>General diagnostic and treatment algorithm</i>	34
<i>Role of nuclear imaging</i>	34
<i>Radioiodine therapy</i>	36
<i>Side effects and radiation precautions</i>	37
<i>Thyroid Cancer</i>	37
<i>Background</i>	37
<i>Treatment overview</i>	37
<i>Role of nuclear imaging and therapy</i>	40
<i>Radioiodine scans</i>	41
<i>Radioiodine therapy</i>	42
<i>Post-therapy scans</i>	43
<i>Side effects and radiation precautions</i>	43
<i>Non-iodine avid disease</i>	43
<i>Conclusion</i>	44

*Chapter Self-Assessment Questions 46*

*Chapter 5 Parathyroid Scintigraphy 48*

*Background 48*

*Parathyroid scintigraphy 48*

*Chapter Self-Assessment Questions 53*

*Chapter 6 Neuroendocrine Tumor Imaging and Therapy 55*

*Introduction 55*

*Background 55*

*Somatostatin receptors 55*

*Somatostatin receptor imaging 56*

*Somatostatin receptor therapy 57*

*Clinical Trials of Peptide Receptor Radionuclide Therapy 57*

*Phase I or II experience 57*

*177*

*Lu-Dotatate Therapy 58*

*Patient selection 58*

*Future directions and controversies 60*

*Performing the therapy 63*

*Efficacy 64*

*Neuroblastoma 64*

*Pheochromocytoma or paraganglioma 64*

*Medullary thyroid cancer 64*

*Conclusion 64*

*Chapter Self-Assessment Questions 67*

*Chapter 7 Central Nervous System 68*

*Introduction 68*

*Clinical Applications 68*

*Cerebrospinal fluid flow imaging 68*

*Brain death 69*

*Epilepsy 70*

*Movement disorders 70*

*Cerebrovascular disease 71*

*Parametric brain SPECT or PET mapping 72*

*Chapter Self-Assessment Questions 77*

*Chapter 8 Bone Scintigraphy 78*

*Introduction 78*

*Normal Biodistribution 78*

*Clinical Applications 78*

*Bone vascularity and viability 79*

*Prosthesis evaluation 80*

*Metabolic bone disease 80*

*Malignant disease 82*

*Extra-Osseous Uptake 83*

*Chapter Self-Assessment Questions 84*

*Chapter 9 Infection and Inflammation 85*

*Introduction 85*

*Basic principles of imaging labeled white blood cell scintigraphy 85*

*Basic principles of imaging FDG 86*

*Clinical imaging strategies in selected clinical settings 87*

*Systemic infection and inflammation 87*

*Localized or organ specific infection and inflammation 89*

*Novel and future aspects 92*

*Nuclear medicine aspects of COVID-19 92*

*Chapter Self-Assessment Questions 97*

*Chapter 10 Cardiovascular Nuclear Medicine 99*

*Myocardial Function 99*

*Myocardial perfusion 100*

*Myocardial Viability 103*

*Infective, Inflammatory, and Deposition-Related Conditions 104*

*Chapter Self-Assessment Questions 108*

*Chapter 11 Pulmonary Scintigraphy 109*

*Introduction 109*

*Clinical Aspects of Pulmonary Embolism 109*

*Overall Imaging Strategies in Pulmonary Embolism 110*

*Practical Aspects of V/Q Scan 110*

*Interpretation of V/Q Scintigraphy—Pulmonary Embolism or No Pulmonary Embolism 111*

*Non-Pulmonary Embolism Use 113*

*Take Home Points 114*

*Chapter Self-Assessment Questions 115*

*Chapter 12 Gastrointestinal & Hepatobiliary Scintigraphy 116*

*Gastrointestinal Functional Studies 116*

*Gastric Emptying Scintigraphy 116*

*Scintigraphic Principle 116*

*General Study Protocol 117*

*Interpretation and Reporting 117*

*Gastroesophageal Reflux and Pulmonary Aspiration 117*

*Scintigraphic principle 118*

*General study protocol 118*

*Interpretation and reporting 118*

*Small Bowel and Colon Transit Studies 118*

*Procedure 118*

*Protocols 118*

*Image analysis 119*

*Salivary Gland Function 120*

*Protocol 122*

*Applications 122* Contents xvii

*Meckel's Scintigraphy 123*

*Scintigraphic principle 123*

*General study protocol 123*

*Interpretation and reporting 124*

*Biliary Acid Recirculation 124*

*Scintigraphic principle 124*

*General study protocol 124*

*Protein-losing Enteropathy 124*

*Scintigraphic principle 124*

*General study protocol 125*

*Interpretation and reporting 125*

*Gastrointestinal Bleeding Scintigraphy 125*

*Scintigraphic principle 126*

*General study protocol 126*

*Interpretation and reporting 126*

*Hepatobiliary and splenic scintigraphy 127*

*Cholescintigraphy 127*

*Radiopharmaceuticals 128*

*Indications 128*

*Contraindications 128*

*General study protocol 128*

*Postprandial epigastric pain 128*

*Postsurgical complications 129*

*Biliary atresia 130*

*Choledochal cysts 131*

*Liver function and surgical planning pre-liver resection 131*

*Liver Assessment Before Selective Internal Radiation Therapy 132*

*Other applications 132*

*Splenic Scintigraphy 133*

*Indications 133*

*Protocol 133*

*Acknowledgment 134*

*Chapter Self-Assessment Questions 135*

*Chapter 13 Renal Scintigraphy 136*

*Radiopharmaceuticals 136*

*Technetium-99m diethylenetriaminepentaacetic acid 136*

*Iodine-131 orthoiodohippurate 136*

*Technetium-99m mercaptoacetyltriglycine 136*

*Technetium-99m dimercaptosuccinic acid 136*

*Fluorine-18 fluorodeoxyglucose 137*

*Normal Renal Function 137*

<i>Clinical Applications</i>	137
<i>Renal failure</i>	137
<i>Renal infection</i>	137
<i>Renal obstructive disease</i>	138
<i>Renovascular disease</i>	139
<i>Renal transplant assessment</i>	139
<i>Renal Cancer</i>	140
<i>Chapter Self-Assessment Questions</i>	142
<i>xviii Contents</i>	
<i>Chapter 14 Positron Emission Tomography (PET), PET/CT, and PET/MRI</i>	143
<i>Introduction</i>	143
<i>Radiopharmaceuticals and instrumentation</i>	143
<i>Positron emission tomography radiopharmaceuticals</i>	146
<i>Technical considerations</i>	148
<i>Other positron emission tomography radiopharmaceuticals in oncologic applications</i>	150
<i>Myocardial perfusion positron emission tomography tracers</i>	151
<i>Clinical applications in oncology</i>	152
<i>Genitourinary malignancies</i>	157
<i>Prostate</i>	158
<i>Breast cancer</i>	159
<i>Cardiology applications</i>	163
<i>NeuroPET</i>	164
<i>Interictal seizure localization</i>	165
<i>Summary</i>	168
<i>Chapter Self-Assessment Questions</i>	178
<i>Chapter 15 Lymphoscintigraphy</i>	179
<i>Lymphoscintigraphy Principles</i>	179
<i>Cancer lymphatic drainage</i>	180
<i>Lymphedema</i>	180
<i>Reverse Lymphatic Mapping</i>	180
<i>Chapter Self-Assessment Questions</i>	183
<i>Chapter 16 Radio-Theranostics</i>	184



<i>Introduction</i>	184
<i>Radio-theranostic pairs</i>	184
<i>Pseudo–radio-theranostic pairs</i>	185
<i>Radio-theranostics in the clinic</i>	187
<i>Summary</i>	192
<i>Chapter Self-Assessment Questions</i>	194
<i>Chapter 17 Essentials of Pediatric Nuclear Medicine</i>	195
<i>Introduction</i>	195
<i>Radiopharmaceutical Dosage and Radiation Dose</i>	195
<i>Distraction Techniques, Sedation, and General Anesthesia</i>	196
<i>Thyroid</i>	196
<i>Congenital hypothyroidism</i>	196
<i>Graves’ disease</i>	200
<i>Differentiated thyroid cancer</i>	200
<i>Urinary Tract</i>	202
<i>Congenital anomalies of the kidneys and urinary tracts</i>	202
<i>Dimercaptosuccinic Acid</i>	213
<i>Voiding cystography</i>	213
<i>Hepatobiliary System and Spleen</i>	215
<i>Neonatal biliary atresia</i>	215
<i>Other pediatric-specific hepatobiliary and splenic pathologies</i>	215
<i>Gastrointestinal Tract</i>	216
<i>Contents</i>	xix
<i>Gastroesophageal reflux scintigraphy, gastric emptying scintigraphy, and radionuclide salivagram</i>	216
<i>Ectopic gastric mucosa in a Meckel diverticulum</i>	219
<i>Musculoskeletal System</i>	221
<i>Bone stress injuries: Stress reactions and stress fractures</i>	221
<i>Back pain and spondylolysis</i>	221
<i>Non-accidental trauma</i>	223
<i>Complex regional pain syndrome</i>	229
<i>Functional Imaging in Pediatric Oncology</i>	229
<i>Metaiodobenzylguanidine in neuroblastoma</i>	229

*18F-FDG PET/CT in pediatric neoplasms 232*

*Infection and Inflammation 232*

*Central Nervous System 239*

*Epilepsy 239*

*Nuclear medicine cerebrospinal fluid shunts 239*

*Conclusion 239*

*Chapter Self-Assessment Questions 247*

*Chapter 18 Quality Assurance of Nuclear Medicine Instrumentation 248*

*Introduction 248*

*Gamma Camera Uniformity Test 248*

*Resolution and Linearity 249*

*Center of rotation 249*

*SPECT system performance evaluation 249*

*Quality assurance of CT scanners 249*

*Quality assurance of PET scanners 250*

*Blank scans 250*

*Normalization scans 250*

*Radioactivity concentration calibration 250*

*PET/CT performance evaluation 251*

*Summary of Quality Assurance of Nuclear Medicine Instrumentation 251*

*Chapter Self-Assessment Questions 252*

*Chapter 19 Nuclear Medicine Procedures in the Pregnant and Lactating Patient 253*

*Introduction 253*

*What Are the Risks of Radiation in Pregnancy? 253*

*Recommendations regarding fetal radiation exposure 253*

*Radiopharmaceutical distribution and dosimetry in the pregnant patient 253*

*Imaging for suspected pulmonary embolism in pregnancy 255*

*Radioiodine distribution and dosimetry in the pregnant patient 257*

*Example Cases of*

*131*

*I Treatments in Pregnant Patients from the United States*

*Nuclear Regulatory Commission Office of Nuclear Material Safety  
and Safeguards 258*

*Decision-Making Regarding Imaging with Radiopharmaceuticals in  
the Pregnant Patient 260*

*Radioisotopes and the lactating patient 260*

*Chapter Self-Assessment Questions 264*

*Index 267*